News

Jim Cramer on Pfizer (PFE) – “Caught in a Vortex, but I’m Sticking with Seagen and Dr. Bourla”
We recently published a list of 13 Stocks on Jim Cramer’s Radar Recently. In this article, we are going to take a look at ...
Pfizer subsidiary receives A2 rating from Moody’s with stable outlook
Investing.com -- Moody’s Ratings has assigned an A2 rating to Pfizer Netherlands International Finance B.V. (PNIF BV), a ...
Pfizer: Bearish Catalysts Brewing
Pfizer's 7.45% dividend yield can't offset weak growth, declining EPS, and patent risks. Read more on PFE and why analysts ...
Investing Snacks9h
Pfizer Slims Its Wallet, Terns Tries to Fly Anyway
BMO Capital cut Terns Pharmaceuticals' price target from $26 to $15, citing costlier capital conditions despite maintaining ...
EU court annuls rejection of bid for EU's von der Leyen vaccine messages with Pfizer
Europe's second-top court on Wednesday dismissed the European Commission's rejection of a New York Times' request to access text messages between its President Ursula von der Leyen and Pfizer CEO ...
Why Pfizer Inc. (PFE) Is Among the Best Pharma Stocks to Invest in Amid the Domestic Manufacturing Boom
We recently published a list of Domestic Manufacturing Boom: 12 Best Pharma Stocks to Invest in Now. In this article, we are ...
One estimate of the profit hit from Trump's executive order on drug pricing
Analysts are still crunching the numbers on the impact of President Donald Trump's executive order from Monday on drug pricing. HSBC analyst Rajesh Kumar says a 20% price cut in government channels ...